Marotta Asset Management Reduces Stock Position in Genmab A/S Sponsored ADR $GMAB

Marotta Asset Management lessened its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 10.7% in the 2nd quarter, Holdings Channel.com reports. The firm owned 12,084 shares of the company’s stock after selling 1,448 shares during the period. Marotta Asset Management’s holdings in Genmab A/S were worth $250,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Rhumbline Advisers grew its holdings in Genmab A/S by 3.2% in the 1st quarter. Rhumbline Advisers now owns 16,956 shares of the company’s stock valued at $332,000 after buying an additional 532 shares in the last quarter. Foresight Group Ltd Liability Partnership acquired a new position in shares of Genmab A/S during the 1st quarter valued at about $954,000. Scientech Research LLC grew its holdings in shares of Genmab A/S by 209.5% in the first quarter. Scientech Research LLC now owns 34,611 shares of the company’s stock valued at $678,000 after purchasing an additional 23,428 shares during the period. Cubist Systematic Strategies LLC increased its position in Genmab A/S by 112.4% during the first quarter. Cubist Systematic Strategies LLC now owns 1,258,143 shares of the company’s stock worth $24,634,000 after purchasing an additional 665,893 shares during the last quarter. Finally, Graham Capital Management L.P. raised its stake in Genmab A/S by 28.9% during the first quarter. Graham Capital Management L.P. now owns 71,452 shares of the company’s stock worth $1,399,000 after purchasing an additional 16,035 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on GMAB shares. Truist Financial increased their price target on shares of Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 8th. Zacks Research lowered Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Wall Street Zen raised Genmab A/S from a “hold” rating to a “buy” rating in a research note on Monday, July 28th. Finally, HC Wainwright upped their price target on Genmab A/S from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $39.25.

Genmab A/S Stock Performance

Genmab A/S stock opened at $27.82 on Friday. The company has a market capitalization of $17.85 billion, a PE ratio of 13.98, a price-to-earnings-growth ratio of 1.67 and a beta of 0.93. Genmab A/S Sponsored ADR has a fifty-two week low of $17.24 and a fifty-two week high of $28.75. The firm has a 50 day moving average price of $23.55 and a 200 day moving average price of $21.65.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The company had revenue of $925.00 million for the quarter, compared to analysts’ expectations of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.